The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review

Table 1 The characteristics of included RCTs

Study ID	Sample size		Interventions		Durations	Outcomes
	Experimental group	Control group	Experimental group	Control group
Azuma 2005	72	35	Pirfenidone 1800 mg/d	Placebo	9 months	Pirfenidone is not yet able to increase the lowest SpO₂ in 6MWT, but it can increase the VC of IPF patients
CAPACITY 004 2011	174	174	Pirfenidone 2403 mg/d	Placebo	72 weeks	Pirfenidone slowed the decline of FVC and prolonged the PFS period, but did not significantly increase the lowest SpO 2 of 6MWD and 6MWT
CAPACITY 006 2011	171	173	Pirfenidone 2403 mg/d	Placebo	72 weeks	Pirfenidone did not increase the lowest SpO 2 in FVC, PFS phase and 6MWT, but pirfenidone could reduce the decline of 6MWD
Huang 2015	38	38	Pirfenidone 1800 mg/d	Placebo	48 weeks	The pirfenidone group can significantly prolong the PFS period, without significantly delaying the decline of FVC, and not increasing the lowest SpO₂ of 6MWD and 6MWT
King 2014 (ASCEND)	278	277	Pirfenidone 1800 mg/d	Placebo	52 weeks	Pirfenidone can slow down the decline of FVC and 6MWD, and significantly prolong the PFS
Lei 2018	20	20	Pirfenidone 1200 mg/d	Blank control	48 weeks	Pirfenidone can delay the decline of FVC
Li 2015	43	44	Pirfenidone 1200 mg/d	Placebo	48 weeks	Pirfenidone can improve FVC and slow down the decline of 6MWD
Li 2016	24	24	Pirfenidone 1200 ~ 1800 mg/d	Blank control	6 months	Pirfenidone can improve FVC and increase 6MWD
Taniguchi 2010	110	109	Pirfenidone 1800 mg/d	Placebo	52 weeks	Pirfenidone can slow down the decline of VC in IPF patients and prolong the PFS

ISSN: 2047-783X